Summary Murine monoclonal antibody CF511, raised against human ovarian clear cell carcinoma, detects a glycoprotein (Mr 600 kDa) called CF511 antigen which is elevated in the serum of many patients with ovarian carcinoma. A competitive enzyme-linked immunosorbent assay was developed to detect CF511 antigen in human serum and used to detected CF511 antigen in subjects with ovarian carcinoma and other diseases. No raised levels (<18 unit (U) ml-') of the antigen were found in the serum of 220 normal individuals or of patients with germ cell tumours (n = 6), granulosa theca cell tumour (n = 1), gastric carcinomas (n = 10) and colo-rectal carcinomas (n = 8). Raised serum levels of CF511 antigen were found in 6/46 patients (13.0%) with benign gynaecological tumours (including endometriosis or ovarian cyst), in 5/7 patients (71.4%) with breast carcinoma and 16/21 (76.2%) lung carcinoma patients. In patients with ovarian carcinoma, 42.3% (11/26) of stage I and II, and 96.0% (24/25) of stage III and IV had levels of > 18 U ml-'. In all patients with serial determination of CF511 antigen levels before and after the surgery, the levels of antigen correlated with the clinical course of disease. Determination of CF511 antigen levels may be useful for detection of ovarian carcinoma as well as lung and breast carcinomas and for monitoring progress of disease and response to therapy.
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Ovarian carcinoma is the most lethal of all gynaecological carcinomas. However, the disease is curable if diagnosed at an early stage, and early detection is associated with a better prognosis (Petterson, 1985) . It is therefore important to develop new methods for the early detection of the diseases. Among many tumour markers developed for serum diagnosis of ovarian carcinoma, CA125 has been known as the most useful marker (Zanaboni et al., 1987) . However, the false positive rate of CA125 in sera from patients with endometriosis has been rather high (Niloff et al., 1984; Takahashi et al., 1986) .
We have developed a serum test for the detection of ovarian carcinoma based on the use of a monoclonal antibody CF511 (Ohkawa et al., 1989 Competitive ELISA CF511 antigen-rich fraction used in the competitive ELISA was extracted from HAC 2 cells by 1 M urea in 10 mM sodium phosphate, pH 7.0, 150 mM NaCl (PBS) for 20 min at 4°C (Kishi et al., 1980) . The urea-extracted solution was dialysed extensively against PBS. Protein was assayed by Lowry et al. (1951) . The antigen solution (1 lag ml-') coated onto 96-well microtiter plates (Nunc, Denmark) at 4°C for 7 h. After washing the plates with PBS, the wells were treated with 5% skimmed milk in 20 mM Tris HCl, pH 7.5, 0.5 M NaCl (TBS) for 1 h at room temperature to block protein binding sites. The 50 p1l of patient's serum (1/10 diluted with 1% bovine serum albumin in TBS) was preincubated with the same volume of alkaline phosphatase-labelled CF5 1I antibody (500 ng ml-') for 2 h at room temperature. Alkaline phosphatase-labelled CF51 1 was prepared with purified CF511 conjugated to calf intestinal alkaline phosphatase (Boehringer Mannheim, Germany) using glutaraldehyde according to the method previously reported by Schreier et al. (1980) . Fifty ftl of the incubation mixture was then put into the antigen-coated wells and incubated further 17 h at 4°C. After five repeated washing steps with 0.05% Tween 20 in TBS, 100p1 of p-nitrophenylphosphate in 10mM diethanolamine, pH 9.5, 0.5 mM MgCI2 as a substrate was added and the absorbance at 405 nm was determined after 30 min of colour development with a microplate reader (MPRA4, TOSOH, Japan). The results were expressed in terms of a unit (U) ml-' calculated from the titration curve of the standard antigen. One pg ml-' of partially purified antigen measured by Lowry's method (Lowry et al., 1951) was defined as 100 U ml-' of CF511 antigen. A sample was considered to be positive when the value was beyond the normal range, namely, the mean plus two standard deviations, for control samples from healthy volunteers. CA125 and CA72-4 were determined using the commercially available immunoassay kits (Centocor, Malvern, PA, USA).
Results
Establishment of competitive ELISA A typical standard curve for CF511 antigen assay is shown in Figure 1 . The mean intra-assay coefficient of variation Figure 2 . The cut-off value was set at 18 U ml-' based on the normal range (mean + 2 s.d. = 7.9 + 4.9 x 2 = 17.7) for control samples from 220 normal individuals. No case was positive in normal individuals.
Ovarian carcinoma Sixty-nine per cent of sera from patients showed elevated levels of antigen ( Figure 2 ). As shown in Figure 3 , moderately raised CF5 11 antigen levels were detected in patients with stage I (Petterson, 1985 7 days following the operation (Figure 5) . A representative example is described. The patient with mucinous cystadenocarcinoma, stage IV, was monitored for CF511 antigen and CA125 level over 8 months (Figure 6 ). After surgery followed by cytotoxic chemotherapy, her disease was arrested and had a probable partial response for a period of 4 months. During that time, there was a corresponding fall in CF511 antigen level from 55 U ml-' to 12 U ml-'. However, during the following 1 month, the CF511 antigen levels rose again to 19 U ml-' without elevation of CA125 despite the disease remaining stable and it was not until 2 months later that disease progression was first clinically detected by CT scan. The antigen levels continued to rise for 3 months to 75 U ml-'.
Correlation between serum CF511 antigen levels and CA72-4 or CA125 levels Serum levels of CF511 antigen, CA72-4 and CA125 were assayed simultaneously in 22 patients with ovarian carcinomas and nine patients with pathologically confirmed advanced pelvic endometriosis with uterine fibroids (these cases contained in 39 cases of uterine fibroids with endometriosis). There was no significant correlation was among them in ovarian carcinoma patients. In endometriosis the positive rates of CA125 were moderately high (6/9) compared with those of CF511 antigen (1/9) ( Figure 7 ). A serum assay for ovarian carcinoma has been described, based on the detection of a CF511 antigen, a high molecular weight 600 kDa glycoprotein without crossreacting to CA125, using monoclonal antibody CF511. The assay was formulated using a standard dilution of purified monoclonal antibody, as purified antigen was unavailable. A competitive ELISA was developed and the assay has shown that elevated serum levels of CF511 antigen are present in most patients with advanced ovarian carcinoma, however lower but elevated antigen levels are also found in the sera from one third of the patients with early stage diseases. The arbitarily chosen cut-off values of > 18 U ml-' resulted in a specificity of 3.6% false positives and a sensitivity of 68.6% true positives. As the immune reaction between CF511 antigen and antibody was not inhibited by the addition of commercially available well-recognised antigen (CA125, CAl9-9, CA15-3, Du-PAN-2, SLX and CSLEX) (Ohkawa et al., 1989) , CF511 antigen is different from these antigens. The CF511 reactivity is distinguished from that of CA72-4 (Thor et al., 1986) and no significant correlation between CA125 and CF511 antigen levels was also demonstrated (Figure 7) . Furthermore CF511 assay has a low positive frequency in benign ovarian cyst (0%) and endometriosis (11%). High frequency of false-positive rate in endometriosis in CA125 (70-90%) (Takahashi et al., 1986 ) is a disadvantage of CA125 in the diagnosis of ovarian carcinomas. These studies demonstrate the clinical advantage of combination assay with CF511 and other markers in the diagnosis and monitoring of ovarian carcinomas. CF511 antigen levels were also elevated in the sera from patients with breast carcinoma as well as lung carcinoma tested. In this respect, CF511 assay may be clinically useful for cancer detection and more extensive studies are necessary to confirm the usefulness of this assay.
